Therapeutic potential of bimatoprost for the treatment of eyebrow hypotrichosis

Abstract

Eyebrows serve as a key feature of the face and have many roles, including cosmetic appearance and social communication. Eyebrow hypotrichosis, which refers to reduction or absence of the eyebrow hair, could be a major problem that leads to negative functional, psychological, and social consequences. Bimatoprost is an ophthalmic prostamide analog that is approved by the United States Food and Drug Administration for the treatment of eyelash hypotrichosis. Its proposed mechanism is stimulation of the prostaglandin receptor in dermal papilla and melanocyte, thus leading to a prolonged anagen phase and increased melanogenesis. The hair follicle then increases in thickness, length, and darkness. The efficacy of bimatoprost for the treatment of eyebrow hypotrichosis has been supported by well-controlled studies. Bimatoprost, which is noninvasive, effective, and well tolerated, is worth considering as a treatment option for eyebrow hypotrichosis.

Keywords: bimatoprost; eyebrow; hair; hypotrichosis; prostaglandin; prostamide.

Figure 1

The algorithm reveals the clinical approach of eyebrow hypotrichosis. Abbreviations: AA, alopecia areata; AD, atopic dermatitis; AE, anagen effluvium; BCC, basal cell carcinoma; CTCL, cutaneous T-cell lymphoma; DLE, discoid lupus erythematosus; FFA, frontal fibrosing alopecia; MM, malignant melanoma; SCC, squamous cell carcinoma; SD, seborrheic dermatitis; TE, telogen effluvium; TTM, trichotillomania.

Figure 2

Chemical structure of bimatoprost.